Related Experiment Video

Updated: May 9, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics

Alexandra Bailey1, David F McDermott

  • 1Beth Israel Deaconess Medical Center, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA. asbailey@bidmc.harvard.edu

Cancer Journal (Sudbury, Mass.)
|July 23, 2013
PubMed

Insights

Immune checkpoint inhibitors, such as nivolumab, are being developed for metastatic renal cell carcinoma by targeting programmed death 1 and cytotoxic T-lymphocyte antigen 4 pathways. These therapies aim to enhance anti-cancer immune responses, though managing their unique toxicities and identifying predictive biomarkers remain key challenges.

Area of Science:

  • Immunotherapy
  • Oncology
  • Nephrology

Background:

  • Metastatic renal cell carcinoma (mRCC) treatment is evolving with novel immunotherapeutic approaches.
  • Immune checkpoint inhibitors (ICIs) target pathways like programmed death 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) to restore anti-tumor immunity.
  • These agents offer a promising strategy for achieving durable responses in advanced kidney cancer.

Purpose of the Study:

  • To review the development and clinical application of ICIs in metastatic renal cell carcinoma.
  • To discuss the potential benefits and challenges associated with ICI therapy in mRCC.
  • To highlight the ongoing research into predictive biomarkers for patient selection.

Main Methods:

  • Review of current clinical trials (Phases I, II, and III) involving ICIs for mRCC.
  • Analysis of the mechanisms of action for PD-1 and CTLA-4 inhibitors.
  • Examination of the unique toxicity profiles and management strategies for ICIs.

Main Results:

  • Several ICIs targeting PD-1/PD-L1 and CTLA-4 pathways are under investigation for mRCC.
  • Nivolumab is currently in Phase III testing, indicating significant clinical development.
  • Early studies suggest ICIs can improve immune response against cancer, potentially leading to durable remissions.

Conclusions:

  • Immune checkpoint inhibitors represent a significant advancement in the management of metastatic renal cell carcinoma.
  • Addressing the unique toxicities and identifying predictive biomarkers are crucial for optimizing ICI therapy.
  • ICIs are poised to become a key component in the future treatment landscape for kidney cancer and other solid tumors.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...